BioLife SolutionsBLFS +4.25%72 Current Ratio is 7.30 as of Mar. 2026, which is 63% above its 10-year median of 4.49. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.57 (Fairly Valued). The stock has 5 warning signs investors should review. Among 854 Medical Devices & Instruments companies, BioLife Solutions ranks better than 87.7% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BioLife Solutions's current ratio for the quarter that ended in Mar. 2026 was 7.30.
BioLife Solutions has a current ratio of 7.30. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for BioLife Solutions's Current Ratio or its related term are showing as below:
BLFS'
s Current Ratio Range Over the Past 10 Years
Min: 1.04 Med: 4.49 Max: 19.37
Current: 7.3
During the past 13 years, BioLife Solutions's highest Current Ratio was 19.37. The lowest was 1.04. And the median was 4.49.
BLFS's Current Ratio is ranked better than 87.7% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 2.485
vs BLFS: 7.30
BioLife Solutions (NAS:BLFS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BioLife Solutions Current Ratio Related Terms
BioLife Solutions Current Ratio Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLFS vs KMTS, AZTA, ATRC: Current Ratio Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Current Ratio distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions (BLFS) has a Current Ratio of 7.30 as of Mar. 2026. This is 63% above median its historical median of 4.49. Over the past decade, BioLife Solutions' Current Ratio has ranged from 1.04 to 19.37. According to the industry distribution chart, BioLife Solutions ranks #105 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 12.3%.
Is BioLife Solutions' Current Ratio too high?
BioLife Solutions' current Current Ratio of 7.30 is 63% above median its 10-year median of 4.49. Over the past 10 years, this metric has ranged from a low of 1.04 to a high of 19.37. The Medical Devices & Instruments industry median Current Ratio is 2.49. BioLife Solutions' value of 7.30 is 193.8% above this industry median. Based on the distribution chart, BioLife Solutions ranks #105 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Current Ratio compare to KMTS and AZTA?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #105 out of 854 companies for Current Ratio. This places BioLife Solutions in the top 12% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.49. BioLife Solutions' value of 7.30 is 193.8% above this benchmark. Historically, BioLife Solutions' own Current Ratio has ranged from 1.04 to 19.37 over the past decade. While the company's 10-year median is 4.49 vs. the industry median of 2.49, BioLife Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Current Ratio of 7.30 is 193.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Current Ratio is 7.30, which is 63% above median its own 10-year median of 4.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current Current Ratio is 7.30, which is 63% above median its 10-year median of 4.49 and 193.8% above the Medical Devices & Instruments industry median of 2.49. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Current Ratio is 7.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Current Ratio: 7.30 (63% above median its 10-year median of 4.49)
GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
Industry Position: 193.8% above the Medical Devices & Instruments median (#105 of 854)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
